Cas No.: | 1140898-87-8 |
Chemical Name: | BMS-823778 free base |
Synonyms: | 8JYO8VTR11;2-[3-[1-(4-chlorophenyl)cyclopropyl]-[1,2,4]triazolo[4,3-a]pyridin-8-yl]propan-2-ol;2-{3-[1-(4-chlorophenyl)cyclopropyl][1,2,4]triazolo[4,3-a]pyridin-8-yl}propan-2-ol;3-[1-(4-Chlorophenyl)cyclopropyl]-alpha,alpha-dimethyl-1,2,4-triazolo[4,3-a]pyridine-8-methanol;2-(3-(1-(4-chlorophenyl)cyclopropyl)-[1,2,4]triazolo[4,3-a]pyridin-8-yl)propan-2-ol;HJG;GTPL10158;EX-;BMS-823778 free base;BMS-823778 hydrochloride;3-[1-(4-Chlorophenyl)cyclopropyl]-α,α-dimethyl-1,2,4-triazolo[4,3-a]pyridine-8-methanol hydrochloride;BMS 823778;BMS-823778-03;BMS823778 |
SMILES: | ClC1C=CC(=CC=1)C1(C2=NN=C3C(=CC=CN23)C(C)(C)O)CC1 |
Formula: | C18H18ClN3O |
M.Wt: | 327.808022975922 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | BMS-823778 (BMS823778) is an orally available, potent and selective inhibitor of 11βHSD-1 with IC50 of 2.3 nM, displays >10,000-fold selectivity over 11βHSD-2; exhibits robust acute pharmacodynamic effects in cynomolgus monkeys (ED50=0.6mg/Kg) and in diet-induced obese (DIO) mice (ED50=34 mg/Kg), also showed excellent inhibition in an ex vivo adipose DIO mouse model (ED50=5.2 mg/Kg). Diabetes Phase 2 Clinical |